Citations

Clear

184 citation(s) found for "Brenner, J".

S510 Time to Relief of Key Abdominal and Bowel Symptoms of Irritable Bowel Syndrome with Constipation: A Post-Hoc Analysis of Randomized Controlled Trials of Linaclotide
Lacy, Brian E. , Ford, Alexander C. , Bartolini, Wilmin , Shea, Elizabeth P., Bochenek, Wieslaw, Boinpally, Ramesh , Ford, Alexander C , Brenner, Darren M. , Wu, James X. , Almansa, Cristina

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S228-S228

10.14309/01.ajg.0000774512.58250.93 Get It

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Mahil, Satveer K. , Dand, Nick , Yiu, Zenas Z N , Zhang, Xian , Strangfeld, Anja , Mateus, Elsa F , Lawson‐Tovey, Saskia , Cuomo, Giovanna , Caprioli, Marta , Cruz-Machado, Ana Rita , Pereira, Ana Carolina Mazeda, Hasseli, Rebecca , Lorenz, Hanns‐Martin , Hoyer, Bimba F. , Trupin, Laura , Rush, Stephanie, Schmajuk, Gabriela , Jacobsohn, Lindsay, Seet, Andrea M. , Emadi, Samar Al, Wise, Leanna , Gilbert, Emily, Valenzuela-Almada, Maria O , Hsu, Tiffany , Sparks, Jeffrey A. , Xavier, Ricardo Machado , Flipo, René‐Marc , Cantagrel, A., Wallace, Zachary S. , Bhana, Suleman , Costello, Wendy, Grainger, Rebecca , Hausmann, Jonathan S. , Sufka, Paul , Machado, Pedro , Barker, Jonathan N., Smith, Catherine , Coker, Bola , Gisondi, Paolo, Jullien, D., Lambert, Jo, McAteer, Helen , Meynell, Freya, Moorhead, Lucy, Naldi, Luigi, Reynolds, Nick J. , Spuls, Phyllis, Vincent, Alexandra , Waweru, H, Reinisch, Walter , Rahier, Jean‐François , Lewis, James D. , Steinwurz, Flávio , Kissous-Hunt, Michele, Modesto, Irene , Konings, Marishka, Dahou, Brahim, Gómez, Gimena, Roberts, Karen , Báez, Roberto Miguel , Coello, Vanessa Viviana Castro , Salinas, María Jezabel Haye , Maldonado, F., Reyes, Alvaro A., Alle, Gelsomina , Tanten, Romina , Ficco, Hernán Maldonado , Tissera, Yohana , Pisoni, Cecilia , Paula, Alba, Albiero, Juan Alejandro, Schmid, María Marcela, Cosatti, Micaela , Gamba, María Julieta , Leandro, Carlevaris, Cusa, María Alejandra, Germán, Noelia, Bellomio, Verónica , Takashima, Lorena , Pera, Mariana , Elkin, M. S. Gálvez , Medina, María Alejandra , Savio, V. , Tessel, Romina Rojas, Alamino, Rodolfo Pérez, Werner, Marina Laura, Ornella, Sofía , Casalla, Luciana, Vega, María Celina De la , Severina, María de los Ángeles , Lucero, Luciana González , Romeo, Cecilia, Barbich, Tatiana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla , Conti, Silvana, Lázaro, María Alicia, Gil, Gustavo Fabián Rodriguez, Risueño, Fabián, Quaglia, María Isabel, Scafati, Julia , Cuchiaro, Natalia Lili, Rebak, J., Pineda, Susana , Calvo, María Elena, Picco, Eugenia, Yanzi, Josefina Gallino , Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta Silvana , Porta, Sabrina , Herscovich, Natalia , Zamora, José Luis Velasco , Kisluk, Boris, Menescardi, Maria Sol Castaños, Gallo, Rosana, Maldini, Carla , Goizueta, Cecilia, Fernandez, Sabrina Solange de la Vega, Aeschlimann, Carolina, Subils, Gisela, Piette, Y, Devinck, Mieke , Maeyaert, Bea, Ribeiro, Francinne Machado , Ribeiro, Sandra Lúcia Euzébio , Trubert, Anne-Marie Chassin, Dong, Lingli , Cajas, Lui, Anić, Branimir, Čulo, Melanie-Ivana , Pavelic, Tea Ahel, Stranski, Kristina Kovacevic, Karanović, Boris , Píchová, Marta, Vassilopoulos, Dimitrios, Melgar, Gabriela Maria Guzman, Király, Márta , Vojdanian, Mahdi, Balbir‐Gurman, Alexandra , Abutiban, Fatemah , Buliņa, Inita , Bukauskienė, Loreta, Montiel, Beatriz E Zazueta, Ortiz, Angel Alejandro Castillo , Tehozol, Erick Adrian Zamora , Rosete, Diana Cervántes, Nares, Eduardo Martín, Reyna, Tatiana S Rodriguez, Gabayet, Marina Rull, Rodríguez, Deshiré Alpízar, Irazoque, Fedra, Jimenez, Xochitl, Bon, Lenny Geurts van, Zijlstra, T. R., Hoekstra, Monique , Adhoubi, Nasra Al , Salim, Babur , Giraldo, Enrique, Salinas, Ariel, Gil, Manuel Ugarte, Flood, Rachael , Felea, Ioana , Filipescu, Ileana, Rednic, Simona , Tamas, Maria Magdelena, Mlynáriková, Vanda , Skamlova, Martina, Žlnay, Martin, Mičeková, Dagmar, Cápová, L, Šteňová, Emὄke , Raffayová, Helena , Belakova, Gabriela, Straková, Eva , Senčarová, Marieta, Žlnayová, Soňa, Sabová, Anna, Spišáková, Daniela, Oetterová, Mária, Lukáčová, Oľga, Bakošová, Martina, Hočevar, Alojzija , Rubio, N. De la Torre , Sancho, Juan José Alegre , Coro, Montserrat Corteguera, García, Juan Carlos Cobeta , Martin, Maria Carmen Torres, Campos, José Luis Michi , Gómez‐Puerta, José A. , Yardimci, Gozd Kubra, İçaçan, Ozan Cemal , Çelik, Selda , Vasylets, Viktoriia, Vandevelde, Claire , Dunt, Sasha, Leeder, Jane, MacPhie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O’Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer , Warner, Elizabeth, Pilcher, James, Patel, Samir J. , Nikiphorou, Elena , Chadwick, Laura , Jones, Caroline Mulvaney, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah , Jatwani, Shraddha , Baig, Sara , Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Pfeifer, Emily, Skemp, Archibald, Wolff, Anne , Cepeda, Eduardo, Todd, Derrick J. , Hare, Denise, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline H. , Daver, Nicole, Harvey, Melissa , Kramer, Neil , Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Davis, William E. , Quinet, Robert, Scopelitis, Evangeline, Toribio, Karen Toribio, Detiege, Tameka Webb, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Zell, JoAnn, Dao, Kathryn H., Ezzati, Fatemeh, Parks, Deborah, Karp, David R. , Quiceno, Guillermo Andrés, Gilbert, Emily L , Sparks, Jeffrey A , Grainger, Rebecca , Hoyer, Bimba F , Wise, Leanna M , Lawson-Tovey, Saskia , Machado, Pedro M , Hausmann, Jonathan S , Hasseli, Rebecca , Xavier, Ricardo M , Hsu, Tiffany Y-T , Strangfeld, Anja , Mateus, Elsa F , Zamora Tehozol, Erick Adrian , Gomez-Puerta, Jose A , Izadi, Zara , Brenner, Erica J. , Yates, Mark , Ungaro, Ryan C. , Agrawal, Manasi , Colombel, Jean‐Frédéric , Gianfrancesco, Milena A , Hyrich, Kimme L , Carmona, Loreto , Klingberg, Eva , Mazeda, Carolina , Pfeil, Alexander , Katz, Patricia , Duarte‐García, Alí , Isnardi, Carolina A , Quintana, Rosana M , Soriano, Enrique Roberto , D'Silva, Kristin M , Patel, Naomi J , Marques, Cláudia Diniz Lopes , Kakehasi, Adriana María , Claudepierre, Pascal , Goupille, Philippe , Liew, Jean W. , Sirotich, Emily , Robinson, Philip C. , Griffiths, Christopher E.M. , Barker, Jonathan N., Yazdany, Jinoos , Kappelman, Michael D. , Bachelez, Hervé , Capon, Francesca , Cruz, Claudia de la , Mason, Kayleigh J. , Meglio, Paola Di , Gelfand, Joel M. , Gisondi, Paolo , Iversen, Lars , Langan, Sinéad , Puig, L. , Torres, Tiago , Tsakok, Teresa , Warren, Richard Bruce , Ng, Siew C. , Gearry, Richard B. , Reinisch, Walter , Lewis, James D , Kaplan, Gilaad G. , Maldonado, Federico N, Nieto, Romina , Gobbi, Carla Andrea , Cogo, Karina, García, Mercedes , Moyano, Sebastián , Bertoli, Ana María , Martiré, María Victoria , Rath, Eva, Piette, Yves, Pinheiro, Marcelo M. , Ibañez, Sebastián , Barešić, Marko , Vencovský, Jiří , Filková, Mária , Hamoud, Hesham Salah , So, Ho , Zepa, Jūlija , Vega‐Morales, David , Reyna, Tatiana Sofía Rodríguez, Nowakowski, Jarosław , Conway, Richard , McCarthy, Géraldine , Filipescu, I., Groseanu, Laura , Macejová, Želmíra , Strakova, Eva, Campos, Jose, Akar, Servet , Yeoh, Su‐Ann , Morgan, Jennifer , Wilson, Jeffrey, Wolff, Anne, Hare, Denise, Calabrese, Cassandra M. , Adams, Christopher, Khosroshahi, Arezou , Ruderman, Eric , Jayatilleke, Arundathi , Bays, Alison , Parks, Deborah

Mayo Clinic

JAMA Network Open | October 20, 2021 | Volume: 4 | Issue: 10 | Pages: e2129639

10.1001/jamanetworkopen.2021.29639 | PMID 34661663 Get It

Abstract 3884: Stroke Subtypes in Hispanic Patients in the NINDS Stroke Genetics Network (SiGN): A Comparison of Two Classification Systems
Katsnelson, Michael , Gardener, Hannah , Malik, Shaneela , Brown, Robert D. , Barrett, Kevin M. , Ossi, Raid G., Biffi, Alessandro , Helenius, Joanna, Huq, Mohammed Saiful, Weissman, Darren, Sheikh, Huma U., Saraf, Neha, Peddareddygari, Leema Reddy , Woo, Daniel , Smoller, Sylvia, Grewal, Raji P., Worrall, Bradford B. , Ay, Hakan , Kittner, Steven J. , Rundek, Tatjana , Sacco, Ralph L. , Southerland, Andrew M. , Arsava, Ethem Murat , Rexrode, Kathryn M. , Huq, Mohammed, Labovitz, Daniel , Rhodes, David , Brenner, David A. , Rosand, Jonathan M. , Arnett, Donna K. , Meschia, James F.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a3884 Get It

Objectives: Identification of gene variants of stroke subtypes is important for the development of tailored ischemic stroke therapies among various ethnic groups. Valid and reliable determination of ischemic stroke subtype is essential for achieving this goal and to standardize a classification scheme across multi-center studies and different populations. Causative Classification System for Ischemic Stroke (CCS) is a novel computerized subclassification tool developed to improve reliability and accuracy of classifying stroke types. The CCS algorithm relies on both phenotypic and causative stroke variables. A Hispanic subset of the SiGN, an important and distinct target population with greater risk of certain stroke subtypes, was evaluated with Trial of Org 10172 in Acute Stroke Treatment (TOAST) and CCS and the agreement between the two classification systems was analyzed. Methods: Over 6000 subjects at 15 sites across US and Europe were enrolled, with TOAST and CCS locally adjudicated. Blood collection and central data quality control (10% central readjudication) were performed on all participants. A subset of Hispanics was analyzed for the purpose of this study and the agreement between the TOAST and CCS were assessed by kappa statistic. Findings: Hispanics (n=595, 10.9%) compared to non-Hispanics (n=5457) were more likely to be younger (63.7 vs. 64.0), male (55% vs. 46%) and have fewer of the traditional stroke risk factors HTN (54% vs. 64%), Afib (11% vs. 14%), DM(23% vs. 25%), CAD(16% vs. 20%) and smoking(19% vs. 22%). While the TOAST showed no differences between stroke subtypes for Hispanic vs. non-Hispanics, in CCS, Hispanics were classified with more of large vessel (22% vs. 20%), cardioembolic (37% vs. 30%) and small vessel strokes (13% vs. 9%) and fewer with undetermined etiology (28% vs. 40%) as compared to non-Hispanics. TOAST and CCS offered moderate correlation across all stroke types in Hispanics: kappa of 0.66 for large artery atherosclerosis, 0.58 for cardioembolic, and 0.58 for small artery occlusion. Conclusion: CCS offers a more sensitive and accurate system for subphenotyping of strokes in Hispanics who tended to have relatively fewer risk factors and unclassified strokes. Further studies correlating the two classification systems and their relation to genotyping data are warranted.
Abstract CT130: Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors
Mita, Monica , Valdes, Frances, Ahn, Daniel H. , Starr, Jason S. , Burnett, Christine, Pelham, Joshua, Anand, Banmeet, Strack, Thomas , Sandri, Andrés Machado, Wainberg, Zev A. , Barve, Minal , Hamilton, Erika , Brenner, Andrew Jacob , Hubbard, Joleen M. , Williams, Eric T. , Tine, Brian A. Van

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: CT130-CT130

10.1158/1538-7445.am2021-ct130 Get It

Abstract Background: Engineered toxin bodies (ETBs), composed of an engineered Shiga-like Toxin A subunit genetically fused to an antibody-binding domain, can force receptor internalization, induce potent cell-kill via enzymatic and permanent inactivation of ribosomes, and may not be subject to resistance mechanisms of other targeted agents. MT-5111, a de-immunized 55 kD ETB targeting HER2 in solid tumors, also binds to an epitope distinct from trastuzumab and pertuzumab, which may permit combination strategies with other HER2 targeting agents. Methods: The primary objective is to determine maximum tolerated dose (MTD) of MT-5111 monotherapy in adult patients (pts) with advanced HER2+ solid tumors. Secondary objectives are PK, efficacy, and immunogenicity. Using a modified 3+3 design, the dose-escalation part of the study includes the following 7 cohorts: 0.5, 1, 2, 3, 4.5, 6.75, and 10 µg/kg. Three dose-expansion cohorts will follow for HER2+ breast cancer, gastro-esophageal cancer, and any other HER2+ tumors. All pts will receive MT-5111 weekly as a 30-min IV infusion in each 21-d treatment (tx) cycle (C) until disease progression (PD), unacceptable toxicity, death, or withdrawn consent (NCT04029922). Results: As of the data cut in December 2020, 16 pts were treated; cancer types included breast (n=6), gastric (n=1), colon (n=1), gallbladder (n=5), and other solid tumors (n=3). Mean age was 64 years (range, 34-78); 37.5% were male. Pts received a median of 4 prior lines of systemic therapies (range, 1-8). No G4 or G5 TEAEs occurred. Six pts had 11 G3 TEAEs; the most common were increased AST and dyspnea (both n=2). Three pts had tx-emergent serious adverse events (abdominal distension [n=1]; dyspnea [n=2]). Tx-related TEAEs occurred in 8 (50%) pts; the most common was fatigue (n=5, 31.3%) and all were ≤ grade 2 in nature, except for one grade 3 event of dyspnea. No cardiac TEAEs, clinically significant changes in cardiac biomarkers (troponin, electrocardiogram, left ventricular ejection fraction), or cases of capillary leak syndrome were observed. Fifteen pts discontinued with PD; 1 pt in cohort 5 (4.5 µg/kg) is on tx with stable disease. To date, no DLTs have been observed and the MTD has not been reached. One pt in cohort 2 (1 µg/kg) had resolution of all hepatic lesions (sub-centimeter lesions pre-tx) at the end of C8; however, the pt came off study due to clinical progression at the end of C10. PK data for the first 5 cohorts matched simulations based on non-human primate studies. Conclusions: MT-5111 was well tolerated with no clinically significant cardiotoxicity. Continued dose escalations are ongoing. Citation Format: Zev A. Wainberg, Monica M. Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel Ahn, Joleen Hubbard, Jason Starr, Christine Burnett, Joshua Pelham, Eric T. Williams, Banmeet S. Anand, Thomas Strack, Andrés Machado Sandri, Brian A. Van Tine. Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT130.
Rare Copy Number Variants (CNVs) and Breast Cancer Risk
Dorling, Leila , Bola, Manjeet, Wang, Qin , Andrulis, Irene L. , Antonenkova, Natalia, Aronson, Kristan J. , Freeman, Laura Beane, Beckmann, Matthias W. , Bojeson, Stig, Chang‐Claude, Jenny , Chenevix‐Trench, Georgia , Collaborators, NBCS, Collée, J. Margriet, Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, Hahen, Eric, Haiman, Christopher A. , Hoppe, Reine, Investigators, ACTB, Investigators, kConFab, Jager, Agnes , Johnson, Nichola , Keeman, Renske , Ko, Yon‐Dschun, Kosma, Veli‐Matti , Kristensen, Vessela N. , Kubelka‐Sabit, Katerina , Kurian, Alison, Larson, Nicole L. , Linet, Martha S. , Łukomska, Alicja, Mannermaa, Arto , Mavroudis, Dimitrios, Park‐Simon, Tjoung‐Won , Peterlongo, Paolo , Plaseska-Karanfilska, Dijana, Sawyer, Elinor J. , Schmutzler, Rita K., Shibli, Rana , Soucy, Penny, Tomlinson, Ian , Vachon, Celine M. , Wendt, Camilla, Yang, Xiaohong R. , Easton, Douglas F. , Peterlongo, Paolo , Evans, D Gareth , Chenevix-Trench, Georgia , Sawyer, Elinor J , Dennis, Joe , Tyrer, Jonathan P. , Walker, Logan C. , Michailidou, Kyriaki , Ahearn, Thomas U. , Anton‐Culver, Hoda , Arndt, Volker , Behrens, Sabine , Benı́tez, Javier , Bermisheva, Marina , Bojesen, Stig E. , Brenner, Hermann , Castelao, Jose E. , Clarke, Christine L. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Devilee, Peter , Dörk, Thilo , Dossus, Laure , Eliassen, A. Heather , Eriksson, Mikael , Figueroa, Jonine D. , Fletcher, Olivia , Fritschi, Lin , Gabrielson, Marike , Gago-Domínguez, Manuela , García‐Closas, Montserrat , Giles, Graham G. , González‐Neira, Anna , Guénel, Pascal , Hall, Per N , Hollestelle, Antoinette , Hoppe, Reiner , Hopper, John L. , Howell, Anthony , Jakubowska, Anna , John, Esther M. , Jones, Michael E. , Jung, Audrey , Kaaks, Rudolf , Хуснутдинова, Э. К. , Kitahara, Cari M. , Koutros, Stella , Kraft, Peter , Lambrechts, Diether , Manoukian, Siranoush , Margolin, Sara , Milne, Roger L. , Muranen, Taru , Murphy, Rachel A. , Nevanlinna, Heli , Olson, Janet E. , Olsson, Håkan , Perou, Charles M. , Pylkäs, Katri , Rennert, Gad , Saloustros, Emmanouil , Sandler, Dale P. , Schmidt, Marjanka K. , Smeets, Ann , Southey, Melissa C. , Swerdlow, Anthony J. , Tamimi, Rulla M. , Taylor, Jack A. , Teras, Lauren R. , Terry, Mary Beth , Troester, Melissa A. , Truong, Thérèse , Vachon, Celine M. , Wendt, Camilla, Winqvist, Robert , Wolk, Alicja , Zheng, Wei , Ziogas, Argyrios , Simard, Jacques , Dunning, Alison M. , Pharoah, Paul D.P.

Mayo Clinic

No container title available | June 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-602209/v1 Get It

Abstract BackgroundCopy number variants (CNVs) are pervasive in the human genome but potential disease associations with rare CNVs have not been comprehensively assessed in large datasets. We analysed rare CNVs in genes and non-coding regions for 86,788 breast cancer cases and 76,122 controls of European ancestry with genome-wide array data.ResultsGene burden tests detected the strongest association for deletions in BRCA1 (P= 3.7E-18). Nine other genes were associated with a p-value < 0.01 including known susceptibility genes CHEK2 (P= 0.0008), ATM (P= 0.002) and BRCA2 (P= 0.008). Outside the known genes we detected associations with p-values < 0.001 for either overall or subtype-specific breast cancer at nine deletion regions and four duplication regions. Three of the deletion regions were in established common susceptibility loci.ConclusionsThis is the first genome-wide analysis of rare CNVs in a large breast cancer case-control dataset. We detected associations with exonic deletions in established breast cancer susceptibility genes. We also detected suggestive associations with non-coding CNVs in known and novel loci with large effects sizes. Larger sample sizes will be required to reach robust levels of statistical significance.
Association Between Smoking and Molecular Subtypes of Colorectal Cancer
Wang, Xiaoliang , Amitay, Efrat L. , Harrison, Tabitha A. , Banbury, Barbara L. , Berndt, Sonja I. , Brenner, Hermann , Buchanan, Daniel D. , Campbell, Peter T. , Cao, Yin , Chang‐Claude, Jenny , Gallinger, Steven , Giannakis, Marios , Gunter, Marc J. , Nishihara, Reiko , Phipps, Amanda I. , Slattery, Martha L. , Song, Mingyang , Thibodeau, Steven, Guelpen, Bethany Van , Woods, Michael O. , Hoffmeister, Michael , Peters, Ulrike , Amitay, Efrat L , Chang-Claude, Jenny , Gunter, Marc J , Jenkins, Mark A , Moreno, Victor , Ogino, Shuji , Sakoda, Lori C , Schoen, Robert E , Song, Mingyang , Sun, Wei , Thibodeau, Steven N, Toland, Amanda Ewart , Woods, Michael O , Hoffmeister, Michael , Buchanan, Daniel D , Campbell, Peter T , Cao, Yin , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Wang, Xiaoliang , Chan, Andrew T. , Giles, Graham G. , Hopper, John L. , Jenkins, Mark A. , Lin, Yi , Moreno, Vı́ctor , Newcomb, Polly A. , Sakoda, Lori C. , Schoen, Robert E. , Sun, Wei , Hsu, Li

Mayo Clinic

JNCI Cancer Spectrum | June 13, 2021 | Volume: 5 | Issue: 4 | Pages: No page available

10.1093/jncics/pkab056 | PMID 34377935 Get It

Abstract Background Smoking is associated with colorectal cancer (CRC) risk. Previous studies suggested this association may be restricted to certain molecular subtypes of CRC, but large-scale comprehensive analysis is lacking. Methods A total of 9789 CRC cases and 11 231 controls of European ancestry from 11 observational studies were included. We harmonized smoking variables across studies and derived sex study–specific quartiles of pack-years of smoking for analysis. Four somatic colorectal tumor markers were assessed individually and in combination, including BRAF mutation, KRAS mutation, CpG island methylator phenotype (CIMP), and microsatellite instability (MSI) status. A multinomial logistic regression analysis was used to assess the association between smoking and risk of CRC subtypes by molecular characteristics, adjusting for age, sex, and study. All statistical tests were 2-sided and adjusted for Bonferroni correction. Results Heavier smoking was associated with higher risk of CRC overall and stratified by individual markers (Ptrend &lt; .001). The associations differed statistically significantly between all molecular subtypes, which was the most statistically significant for CIMP and BRAF. Compared with never-smokers, smokers in the fourth quartile of pack-years had a 90% higher risk of CIMP-positive CRC (odds ratio = 1.90, 95% confidence interval = 1.60 to 2.26) but only 35% higher risk for CIMP-negative CRC (odds ratio = 1.35, 95% confidence interval = 1.22 to 1.49; Pdifference = 2.1 x 10-6). The association was also stronger in tumors that were CIMP positive, MSI high, or KRAS wild type when combined (Pdifference &lt; .001). Conclusion Smoking was associated with differential risk of CRC subtypes defined by molecular characteristics. Heavier smokers had particularly higher risk of CRC subtypes that were CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.
Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials
Shah, Eric D. , Lacy, Brian E. , Chey, William D. , Shah, Eric D , Chang, Lin , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | May 28, 2021 | Volume: 116 | Issue: 8 | Pages: 1601-1611

10.14309/ajg.0000000000001313 | PMID 34047303 Get It

INTRODUCTION: Tegaserod was the first US Food and Drug Administration–approved drug for irritable bowel syndrome with constipation (IBS-C) in women and was recently reapproved for use. Recognizing that clinical trials were performed almost 20 years ago, we performed an integrated analysis on patient-reported outcomes relevant to current practice including previously unpublished data. METHODS: Data from 4 12-week, randomized, placebo-controlled trials evaluating tegaserod 6 mg b.i.d. in patients with IBS-C were pooled. We analyzed 2 groups: all women (overall population) and women younger than 65 years without a history of cardiovascular ischemic events (indicated population). The primary end point was subjective global assessment of IBS-C symptom relief. Responders rated themselves as “considerably” or “completely” relieved ≥50% of the time or at least “somewhat relieved” 100% of the time over the last 4 weeks. RESULTS: The overall and indicated populations included 2,939 (tegaserod [n = 1,478]; placebo [n = 1,461]) and 2,752 (tegaserod [n = 1,386]; placebo [n = 1,366]) participants, respectively. The pooled odds ratios (95% confidence interval) for clinical response during the last 4 weeks in the overall and indicated populations with tegaserod were 1.37 (1.18, 1.59; P < 0.001) and 1.38 (1.18, 1.61; P < 0.001). In the overall and indicated populations, clinical response rates for tegaserod during the last 4 weeks were 43.3% and 44.1% versus 35.9% and 36.5% with placebo ( P < 0.001). Adverse events were similar between groups. No significant cardiovascular events related to tegaserod were observed in patients with ≤1 cardiac risk factor. DISCUSSION: Tegaserod 6 mg b.i.d. reduced IBS-C symptoms in overall and US Food and Drug Administration–indicated populations (women aged <65 years with no history of cardiovascular ischemic events).
Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options
Lacy, Brian E. , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | May 16, 2021 | Volume: 116 | Issue: 8 | Pages: 1587-1600

10.14309/ajg.0000000000001266 | PMID 33993133 Get It

Chronic abdominal pain is a common gastrointestinal (GI) symptom that characterizes many functional GI disorders/disorders of gut-brain interaction, including irritable bowel syndrome, functional dyspepsia, and centrally mediated abdominal pain syndrome. The symptoms of abdominal pain in these highly prevalent disorders are often treated with antispasmodic agents. Antispasmodic treatment includes a broad range of therapeutic classes with different mechanisms of action, including anticholinergic/antimuscarinic agents (inhibition of GI smooth muscle contraction), calcium channel inhibitors (inhibition of calcium transport into GI smooth muscle), and direct smooth muscle relaxants (inhibition of sodium and calcium transport). The aim of this review article was to examine the efficacy and safety of antispasmodics available in North America (e.g., alverine, dicyclomine, hyoscine, hyoscyamine, mebeverine, otilonium, pinaverium, and trimebutine) for the treatment of chronic abdominal pain in patients with common disorders of gut-brain interaction. For the agents examined, comparisons of studies are limited by inconsistencies in treatment dosing and duration, patient profiles, and diagnostic criteria employed. Furthermore, variability in study end points limits comparisons. Risk of selection, performance, detection, attrition, and reporting bias also differed among studies, and in many cases, risks were considered “unclear.” The antispasmodics evaluated in this review, which differ in geographic availability, were found to vary dramatically in efficacy and safety. Given these caveats, each agent should be considered on an individual basis, rather than prescribed based on information across the broad class of agents.
Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?
Park, JooYong , Choi, Ji‐Yeob , Chung, Seokang , Song, Nan , Park, Sue K. , Han, Wonshik , Noh, Dong‐Young , Ahn, Sei-Hyun, Lee, Jong Won, Kim, Mi Kyung , Jee, Sun Ha , Wen, Wanqing , Bolla, Manjeet K. , Wang, Qin , Michailidou, Kyriaki , Shah, Mitul , Conroy, Don, Harrington, Patricia, Mayes, Rebecca , Hall, Per , Patel, Alpa V. , Couch, Fergus J. , Sawyer, Elinor J. , Roylance, Rebecca , Bojesen, Stig E. , Flyger, Henrik, Lambrechts, Diether , Baten, Adinda , Matsuo, Keitaro , Ito, Hidemi , Guénel, Pascal , Keeman, Renske , Schmidt, Marjanka K. , Wu, Anna H. , Tseng, Chiu-Chen, Cox, Angela , Investigators, kConFab, Andrulis, Irene L. , Hopper, John L., Wu, Pei‐Ei , Shen, Chen‐Yang , Fasching, Peter A. , Ekici, Arif B. , Muir, Kenneth, Brenner, Hermann , Arndt, Volker , Jones, Michael E. , Swerdlow, Anthony J, Hoppe, Reiner , Ko, Yon-Dschun, Hartman, Mikael , Li, Jingmei , Mannermaa, Arto, Hartikainen, Jaana M. , Benítez, Javier, Haiman, Christopher A. , Dörk, Thilo , Bogdanova, Natalia , Teo, Soo‐Hwang , Taib, Nur Aishah Mohd , Fletcher, Olivia, Johnson, Nichola , Grip, Mervi, Winqvist, Robert , Nevanlinna, Heli , Lindblom, Annika , Wendt, Camilla, Kristensen, Vessela N. , Collaborators, NBCS, Tollenaar, Rob A.�E.�M. , Heemskerk‐Gerritsen, Bernadette A. M. , Bonanni, Bernardo , Hamann, Ute, Manoochehri, Mehdi, Martinez, Maria Elena, Easton, Douglas F., Yoo, Keun-Young, Lambrechts, Diether , Song, Nan , Park, Sue K , Kim, Mi Kyung , Dennis, Joe , Michailidou, Kyriaki , Hall, Per N , Matsuo, Keitaro , Ito, Hidemi , Keeman, Renske , Schmidt, Marjanka K , Fasching, Peter A , Brenner, Hermann , Arndt, Volker , Hartikainen, Jaana M , Dörk, Thilo , Bogdanova, Natalia V , Johnson, Nichola , Nevanlinna, H , Heemskerk-Gerritsen, Bernadette A M , Bonanni, Bernardo , Lambrechts, Diether , Teo, Soo H , Jones, Michael E , Lambrechts, Diether , Cox, Angela , Guénel, Pascal , Hartman, Mikael , Li, Jingmei , Ekici, Arif B , Bojesen, Stig E , Lindblom, Annika , Mohd Taib, Nur Aishah , Sawyer, Elinor J , Choi, Jaesung , Czene, Kamila , Teras, Lauren R. , Couch, Fergus J. , Olson, Janet E. , Truong, Thérèse , Cross, Simon S. , Investigators, kConFab, Southey, Melissa C. , Lophatananon, Artitaya , Ko, Yon‐Dschun, Mannermaa, Arto , González‐Neira, Anna , Fletcher, Olivia , Blomqvist, Carl , Wendt, Camilla, Collaborators, NBCS, Radice, Paolo , Manoochehri, Mehdi, Lacey, James V. , Dunning, Alison M. , Pharoah, Paul D.P. , Kang, Daehee

Mayo Clinic

Cancers | May 14, 2021 | Volume: 13 | Issue: 10 | Pages: 2370

10.3390/cancers13102370 | PMID 34069208 Get It

In this study we aim to examine gene–environment interactions (GxEs) between genes involved with estrogen metabolism and environmental factors related to estrogen exposure. GxE analyses were conducted with 1970 Korean breast cancer cases and 2052 controls in the case-control study, the Seoul Breast Cancer Study (SEBCS). A total of 11,555 SNPs from the 137 candidate genes were included in the GxE analyses with eight established environmental factors. A replication test was conducted by using an independent population from the Breast Cancer Association Consortium (BCAC), with 62,485 Europeans and 9047 Asians. The GxE tests were performed by using two-step methods in GxEScan software. Two interactions were found in the SEBCS. The first interaction was shown between rs13035764 of NCOA1 and age at menarche in the GE|2df model (p-2df = 1.2 × 10−3). The age at menarche before 14 years old was associated with the high risk of breast cancer, and the risk was higher when subjects had homozygous minor allele G. The second GxE was shown between rs851998 near ESR1 and height in the GE|2df model (p-2df = 1.1 × 10−4). Height taller than 160 cm was associated with a high risk of breast cancer, and the risk increased when the minor allele was added. The findings were not replicated in the BCAC. These results would suggest specificity in Koreans for breast cancer risk.
Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study
Hua, Xinwei , Lindström, Sara , Harrison, Tabitha A. , Alwers, Elizabeth , Berndt, Sonja I. , Brenner, Hermann , Buchanan, Daniel D. , Casey, Graham , Chang‐Claude, Jenny , Gallinger, Steven , Goldberg, Richard M. , Gunter, Marc J. , Hoffmeister, Michael , Joshi, Amit D. , Murphy, Neil , Pai, Rish K. , Shi, Qian , Slattery, Martha L. , Song, Mingyang , Peters, Ulrike , Harrison, Tabitha A , Brenner, Hermann , Buchanan, Daniel D , Campbell, Peter T , Chang-Claude, Jenny , Giles, Graham G , Goldberg, Richard M , Hoffmeister, Michael , Milne, Roger L , Pai, R K , Sakoda, Lori C , Schoen, Robert E , Slattery, Martha L , Peters, Ulrike , Gunter, Marc J , Shi, Qian , Murphy, Neil , Song, Mingyang , Dai, James Y. , Lin, Yi , Alberts, Steven R. , Campbell, Peter T. , Giles, Graham G. , Jenkins, Mark A. , Ma, Wenjie , Milne, Roger L. , Sakoda, Lori C. , Schoen, Robert E. , White, Emily E. , Marchand, Loı̈c Le , Chan, Andrew T. , Newcomb, Polly A.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 10, 2021 | Volume: 30 | Issue: 7 | Pages: 1349-1358

10.1158/1055-9965.epi-20-1848 | PMID 33972368 Get It

Abstract Background: A positive association between circulating C-reactive protein (CRP) and colorectal cancer survival was reported in observational studies, which are susceptible to unmeasured confounding and reverse causality. We used a Mendelian randomization approach to evaluate the association between genetically predicted CRP concentrations and colorectal cancer–specific survival. Methods: We used individual-level data for 16,918 eligible colorectal cancer cases of European ancestry from 15 studies within the International Survival Analysis of Colorectal Cancer Consortium. We calculated a genetic-risk score based on 52 CRP-associated genetic variants identified from genome-wide association studies. Because of the non-collapsibility of hazard ratios from Cox proportional hazards models, we used the additive hazards model to calculate hazard differences (HD) and 95% confidence intervals (CI) for the association between genetically predicted CRP concentrations and colorectal cancer–specific survival, overall and by stage at diagnosis and tumor location. Analyses were adjusted for age at diagnosis, sex, body mass index, genotyping platform, study, and principal components. Results: Of the 5,395 (32%) deaths accrued over up to 10 years of follow-up, 3,808 (23%) were due to colorectal cancer. Genetically predicted CRP concentration was not associated with colorectal cancer–specific survival (HD, −1.15; 95% CI, −2.76 to 0.47 per 100,000 person-years; P = 0.16). Similarly, no associations were observed in subgroup analyses by stage at diagnosis or tumor location. Conclusions: Despite adequate power to detect moderate associations, our results did not support a causal effect of circulating CRP concentrations on colorectal cancer–specific survival. Impact: Future research evaluating genetically determined levels of other circulating inflammatory biomarkers (i.e., IL6) with colorectal cancer survival outcomes is needed.